News

Both the organizations will jointly work on research projects to identify new drug candidates. The two parties said they have identified three initial projects with a focus on

TELESTAR will evaluate the safety and tolerability of telotristat etiprate and its effect on symptoms associated with carcinoid syndrome, while top-line data is expected to be reported in

Scleroderma causes fibrosis of skin, joints and internal organs and predominately affects women in mid-life. Resunab is a new, oral specialized pro-resolving mediator drug and it binds to

Under the deal, EMD Serono will pay Opexa additional $3m to support the ongoing Phase IIb clinical trial (Abili-T Trial) in patients with secondary progressive MS (SPMS). The

The deal will see Recro Pharma secure worldwide rights to IV/IM meloxicam and also a contract manufacturing facility, royalty and formulation business in Gainesville, Georgia, US. IV/IM meloxicam

The deal will see advancement of an alternative delivery method for Pfenex’s Px563L-mrPA, using Glide’s solid dose formulation technology. The contract extension is the result of the National

RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications whose active ingredient is Thymosin beta 4 (TB4). The company will receive a $5.92m investment from Global

Under the deal, Concordia will buy substantially all of the commercial assets of Covis Pharma and Covis Injectables, including 18 branded and authorized generic products. Covis drug portfolio

The Emergent-developed MOR209/ES414 molecule is an immunotherapeutic protein, which has shown in preclinical in vitro and in vivo studies its ability to redirect T-cell cytotoxicity towards cells expressing